SCHEMBL31457366

SCHEMBL31457366

O=C(NCc1cc(-c2cccs2)[nH]n1)c1ccccc1OC(F)(F)F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
HCN1 O60741 1/20 0.43
OPRM1 P35372 1/20 0.41
KCNK3 O14649 3/20 0.40
KCNK9 Q9NPC2 3/20 0.40
USP2 O75604 1/20 0.40
MAPT P10636 1/20 0.40
RXFP1 Q9HBX9 1/20 0.39
F2R P25116 1/20 0.39
HPGD P15428 1/20 0.39
BRD4 O60885 1/20 0.39
CREBBP Q92793 1/20 0.39
PTGER2 P43116 1/20 0.39
KDM5A P29375 1/20 0.39
MAPK8 P45983 1/20 0.38
MAPK10 P53779 1/20 0.38
HSD17B13 Q7Z5P4 1/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23623288 1.00 KMT2A (0.47) KMT2AMEN1L3MBTL1HCN1OPRM1
SCHEMBL24177588 0.88 KMT2A (0.46) KMT2AMEN1L3MBTL1USP2MAPT
SCHEMBL23623286 0.86 KMT2A (0.47) KMT2AMEN1L3MBTL1USP2MAPT
SCHEMBL23611754 0.84 KMT2A (0.48) KMT2AMEN1L3MBTL1USP2MAPT
SCHEMBL23623487 0.83 KCNK3 (0.44) HCN1OPRM1KCNK3KCNK9RXFP1
SCHEMBL23623645 0.83 HCN1 (0.43) HCN1OPRM1KCNK3KCNK9RXFP1
SCHEMBL23623486 0.83 HCN1 (0.41) HCN1OPRM1KCNK3KCNK9RXFP1
SCHEMBL24177586 0.82 KMT2A (0.46) KMT2AMEN1L3MBTL1USP2MAPT
SCHEMBL23623491 0.82 OPRM1 (0.42) HCN1OPRM1KCNK3KCNK9RXFP1
SCHEMBL23623344 0.82 OPRM1 (0.42) KMT2AMEN1HCN1OPRM1KCNK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028355-A1 PROTEOLYSIS TARGETING CHIMERA (PROTAC) COMPOSITIONS USING UBIQUITIN CONJUGATING ENZYME LIGANDS BERG, KARA ANN 2026-01-29 US disclosed
US-20250262309-A1 PROTEOLYSIS TARGETING CHIMERA (PROTAC) COMPOSITIONS USING UBIQUITIN CONJUGATING ENZYME LIGANDS BERG, KARA ANN 2025-08-21 US disclosed
CN-119546341-A Proteolytic targeting chimeric (PROTAC) compositions using ubiquitin conjugated enzyme ligands 布普格生物制药公司 2025-02-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250262309-A1 PROTEOLYSIS TARGETING CHIMERA (PROTAC) COMPOSITIONS USING UBIQUITIN CONJUGATING ENZYME LIGANDS UBE3C, UBE3A, MDM2 KMT2A 659/4885MEN1 4190/4885L3MBTL1 1422/4885
US-20260028355-A1 PROTEOLYSIS TARGETING CHIMERA (PROTAC) COMPOSITIONS USING UBIQUITIN CONJUGATING ENZYME LIGANDS UBE2T, UBE3C, UBE2E1 KMT2A 724/4885MEN1 3261/4885L3MBTL1 960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.